• A decision support system for cyclic master surgery scheduling with multiple objectives

      Beliën, Jeroen; Demeulemeester, Erik; Cardoen, Brecht (Journal of Scheduling, 2009)
    • A decision support system for surgery sequencing at UZ Leuven's day-care department

      Cardoen, Brecht; Demeulemeester, Erik (International Journal of Information Technology & Decision Making, 2011)
    • A typology-based decisional framework to support market access and reimbursement decisions for personalised medicines

      Govaerts, Laurenz; Geldof, Tine; Simoens, Steven; Huys, Isabelle (Value in Health. The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017)
      New co-development approaches in personalized medicine challenge current decisional frameworks of health-technology access and reimbursement procedures. We aim to conceptualize an efficient typology-based decisional framework which takes into account the development and market access synchronism between therapeutic (Tx) and diagnostic (Dx) components of personalized medicines.
    • Acute coronary syndrome: What is the cost-effectiveness of prevention, point-of-care technology and telemonitoring?

      Van Dyck, Walter; Gassull, Daniel; Vértes, Gergely; Jain, Prateek; Palaniappan, Muhilan; Schulthess, Duane; Tambuyzer, Erik; Hudson, Richard; Moran, Nuala (Health Policy and Technology, 2012)
      This study is a cost-analysis that calculates the impact of three interventions for patients identified as ‘at risk’ for Acute Coronary Syndrome - a cardio-vascular exercise programme, point-of-care digital diagnostics, and telemonitoring adherence tools. The methodology utilizes a model of the annualized costs of ACS for the entire treatment value chain, and measures the impact of the three interventions by the change in treatment cost, incremental net benefit, and QALY. The results demonstrate that the largest impact is measured when all three interventions are utilized simultaneously producing a cumulative savings of €4424 and 0.126 QALY per patient. We also find a significant decrease in Emergency Room visits by 15% and changes in rates of utilization of Catharization (−59%), Angioplasty (−59%), Bypass (−17%), Medication (−14%) and Rehabilitation (−13%).
    • Admission scheduling in acute care hospitals: Does the practice fit with the theory?

      Gemmel, Paul; Van Dierdonck, Roland (International Journal of Operations and Production Management, 1999)
    • Barco implements platform-based product development in its healthcare division

      Boute, Robert; Van den Broeke, Maud; Deneire, Kristof (Interfaces, 2018)
      In this article, we present how Barco, a global technology company, used an operations research optimization model, which was supported by an efficient solution method, to implement platforms—common structures from which sets of products could be made—for the design and production of its high-tech medical displays. Our optimization model captures all cost aspects related to the use of platforms, thus, it is an objective tool that considers the input from marketing, sales, research and development (R&D), operations, and the supply chain. This comprehensive view allowed Barco to avoid the excessive costs that may result from the implementation of an incorrect platform. Our model supported Barco in determining the elements that should comprise each platform, the number of platforms to develop, and the products to derive from each platform. The results of the project led to reductions in safety stock and increased flexibility due to the use of platforms: R&D can now introduce twice as many products using the same resources, thus increasing Barco's earnings by over 5 million euros annually and reducing product introduction time by nearly 50 percent.
    • Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies

      Michelsen, Sissel; Nachi, Salma; Van Dyck, Walter; Simoens, Steven; Huys, Isabelle (Frontiers in Pharmacology, 2020)
      Background: The challenging market access of high-cost, one-time curative therapies has inspired the development of alternative reimbursement structures, such as outcome-based spread payments, to mitigate their unaffordability and answer remaining uncertainties. This study aimed to provide a broad overview of barriers and possible opportunities for the practical implementation of outcome-based spread payments for the reimbursement of one-shot therapies in European healthcare systems. Methods: A systematic literature review was performed investigating published literature and publicly available documents to identify barriers and implementation opportunities for both spreading payments and for implementing outcome-based agreements. Data was analyzed via qualitative content analysis by extracting data with a reporting template. Results: A total of 1503 publications were screened and 174 were included. Main identified barriers for the implementation of spread payments are reaching an agreement on financial terms while considering 12-month budget cycles and the possible violation of corresponding (inter)national accounting rules. Furthermore, outcome correction of payments is currently hindered by the need for additional data collection, the lack of clear governance structures and the resulting administrative burden and cost. The use of spread payments adjusted by population- or individual-level data collected within automated registries and overseen by a governance committee and external advisory board may alleviate several barriers and may support the reimbursement of highly innovative therapies. Conclusion: High-cost advanced therapy medicinal products pose a substantial affordability challenge on healthcare systems worldwide. Outcome-based spread payments may mitigate the initial budget impact and alleviate existing uncertainties; however, their effective implementation still faces several barriers and will be facilitated by realizing the required organizational changes.
    • Clusters in the biopharmaceutical industry: Toward a new method of analysis

      Erden, Zeynep; von Krogh, Georg (Drug Discovery Today, 2011)
      Clusters are groups of co-located and interconnected firms and institutions linked by commonalities in their strategies and complementarities in their activities and resources. There are several reasons for the geographical clustering of firms in the biopharmaceutical industry. This review unpacks some advantages and disadvantages of cluster participation, and proposes a new method to enable managers and researchers to identify clusters in the biopharmaceutical industry.
    • Comparative and combined effectiveness of innovative therapies in cancer: A literature review

      Geldof, Tine; Rawal, Smita; Van Dyck, Walter; Huys, Isabelle (Journal of Comparative Effectiveness Research, 2019)
      To achieve therapeutic innovation in oncology, already expensive novel medicines are often concomitantly combined to potentially enhance effectiveness. While this aggravates the pricing problem, comparing effectiveness of novel yet expensive (concomitant) treatments is much needed for healthcare decision-making to deliver effective but affordable treatments. This study reviewed published clinical trials and real-world studies of targeted and immune therapies. In total, 48 studies compared and/or combined multiple novel products on breast, colorectal, lung and melanoma cancers. To a great extent, products evaluated in each study were owned by one manufacturer. However, cross-manufacturer assessments are also needed. Next to costs and intensive market competition, the absence of a regulatory framework enforcing real-world multiproduct studies prevents these from being conducted. Trusted third parties could facilitate such real-world studies, for which appropriate and efficient data access is needed.
    • De onthaalomgeving vanuit een service-operations perspectief

      Cardoen, Brecht; Gemmel, Paul; Robberecht, Rein (Hospitals.be, 2013)
    • Editorial special issue Healthcare Operations Management

      Gemmel, Paul; Boaden, R. (International Journal of Operations and Production Management, 2002)
    • Emotional attachment to a hospital: bringing employees and customers into the engagement zone

      Gemmel, Paul; Verleye, Katrien (Journal of Applied Management and Entrepreneurship, 2010)
    • Evaluation of Hospital Service Level Agreements

      Berbée, Rieneke; Gemmel, Paul; Droesbeke, Brenda; Casteleyn, H.; Vandaele, Darline (International Journal of Health Care Quality Assurance, 2009)
    • Evaluation of precision medicine assessment reports of the Belgian healthcare payer to inform reimbursement decisions

      Govaerts, Laurenz; Waeytens, Anouk; Van Dyck, Walter; Simoens, Steven; Huys, Isabelle (International Journal of Technology Assessment in Health Care, 2020)
      Introduction. Precision medicines rely on companion diagnostics to identify patient subgroups eligible for receiving the pharmaceutical product. Until recently, the Belgian public health payer, RIZIV-INAMI, assessed precision medicines and companion diagnostics separately for reimbursement decisions. As both components are considered co-dependent technologies, their assessment should be conducted jointly from a health technology assessment (HTA) perspective. As of July 2019, a novel procedure was implemented accommodating for this joint assessment practice. The aim of this research was to formulate recommendations to improve the assessment in the novel procedure. Methods. This study evaluated the precision medicine assessment reports of RIZIV-INAMI of the last 5 years under the former assessment procedure. The HTA framework for co-dependent technologies developed by Merlin et al. for the Australian healthcare system was used as a reference standard in this evaluation. Criteria were scored as either present or not present. Results. Thirteen assessment reports were evaluated. Varying scores between reports were obtained for the domain establishing the co-dependent relationship between diagnostic and pharmaceutical. Domains evaluating the clinical utility of the biomarker and the cost-effectiveness performed poorly, whereas the budget impact and the transfer of trial data to the local setting performed well. Recommendations. Based on these results we recommend three amendments for the novel procedure. (i) The implementation of the linked evidence approach when direct evidence of clinical utility is not present, (ii) incorporation of a bias assessment tool, and (iii) further specify guidelines for submission and assessment to decrease the variability of reported evidence between assessment reports.
    • Fostering multidisciplinary collaboration in drug discovery

      Erden, Zeynep; Ben-Menahem, Shiko; von Krogh, Georg; Schneider, Andreas; Koch, Guido; Widmer, Hans (Drug Discovery World, 2019)
      Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a challenging exercise in cross-disciplinary collaboration and project coordination. Based on a longitudinal field study of five projects in a leading pharmaceutical company we present a framework outlining the conditions for effective cross-disciplinary collaboration in drug discovery teams. We show that knowledge creation in multidisciplinary teams relies on a combination of formal team structures and informal co-ordination practices. Formal team structures set the boundary conditions for cross-disciplinary co-ordination. Within their boundaries self-managed sub-teams draw on informal co-ordination practices involving cross-disciplinary anticipation, synchronization and triangulation to overcome knowledge boundaries and high uncertainty. We identify five key insights and two questions which are important for managers to consider for fostering multidisciplinary collaboration in drug discovery.
    • Hospital Process Orientation (HPO): The development of a measurement tool

      Gemmel, Paul; Vandaele, Darline; Tambeur, Wim (Total Quality Management & Business Excellence, 2008)
    • Hospital Resource Planning : concepts, feasibility and framework

      Roth, A.; Van Dierdonck, Roland (Production and Operations Management Journal, 1995)
    • Impact of recurrent changes in the work environment on nurses' psychological well-being and sickness absence

      Verhaeghe, Rik; Vlerick, Peter; Gemmel, Paul; Van Maele, G.; De Backer, G. (Journal of Advanced Nursing, 2006)
    • Implementation of a balanced scorecard in an elderly care home: useful or not?

      Sioncke, Gratienne (Total Quality Management & Business Excellence, 2005)